Table 1 The inhibitory effects of ginsenosides on human carboxylesterases in HLM
No. | Compounds | MW | IC50 (μM) | Specificity (hCES1A/hCES2A) | |
|---|---|---|---|---|---|
hCES1A | hCES2A | ||||
1 | DM | 444.40 | 1.99 ± 0.21 | 0.69 ± 0.08 | 3.06 |
2 | C-K | 622.44 | > 100 | 15.46 ± 1.56 | > 6.47 |
3 | Rh2 | 622.44 | > 100 | 5.35 ± 0.56 | > 18.86 |
4 | DMG | 606.45 | 1.76 ± 0.28 | 1.06 ± 0.21 | 0.33 |
5 | R1 | 932.53 | > 100 | > 100 | – |
6 | F2 | 478.03 | > 100 | 14.37 ± 1.59 | 7.26 |
7 | Panaxadiol | 460.39 | 6.95 ± 1.29 | 3.78 ± 0.39 | 1.84 |
8 | PPD | 460.39 | > 100 | 1.34 ± 0.11 | > 75.18 |
9 | Panaxatriol | 476.39 | 34.93 ± 6.16 | 14.59 ± 1.09 | 2.39 |
10 | PPT | 476.39 | > 100 | 0.86 ± 0.09 | > 116.28 |
11 | Rb1 | 1108.60 | > 100 | > 100 | – |
12 | Rg2 | 784.50 | > 100 | > 100 | – |
13 | Rc | 1078.59 | > 100 | 81.66 ± 18.56 | >1.22 |
14 | Rb2 | 1078.59 | > 100 | > 100 | – |
15 | Re | 946.55 | > 100 | > 100 | – |
16 | Rh1 | 638.88 | > 100 | > 100 | – |
17 | Rg3 | 784.50 | > 100 | 10.37 ± 1.17 | > 9.64 |
18 | Rb3 | 1078.59 | > 100 | > 100 | – |
19 | F1 | 638.44 | > 100 | 37.08 ± 5.09 | > 2.70 |
20 | Rg1 | 800.49 | > 100 | > 100 | – |
21 | Rd | 946.55 | > 100 | 14.05 ± 1.78 | > 7.12 |
22 | Ro | 956.50 | > 100 | > 100 | – |
23 | F4 | 766.49 | > 100 | 45.02 ± 6.48 | > 2.22 |
24 | Rh3 | 604.43 | > 100 | 5.85 ± 1.17 | > 17.09 |
25 | Rh4 | 620.43 | > 100 | 62.85 ± 6.72 | > 1.49 |